{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:56:36Z","timestamp":1790664996354,"version":"4.1.0"},"reference-count":96,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2018.9219","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T07:02:41Z","timestamp":1532588561000},"source":"Crossref","is-referenced-by-count":29,"title":["Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)"],"prefix":"10.3892","author":[{"given":"Yu","family":"Yu","sequence":"first","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuwei","family":"Cui","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"key20200714083746_b1-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1158\/1078-0432.CCR-16-0049","article-title":"Emerging opportunities and challenges in cancer immunotherapy","volume":"22","author":"Whiteside","year":"2016","journal-title":"Clin Cancer Res"},{"key":"key20200714083746_b2-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"key20200714083746_b3-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20200714083746_b4-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2015.10.009","article-title":"Immunotherapy and tumor microenvironment","volume":"370","author":"Tang","year":"2016","journal-title":"Cancer Lett"},{"key":"key20200714083746_b5-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200714083746_b6-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","article-title":"Microenvironmental regulation of therapeutic response in cancer","volume":"25","author":"Klemm","year":"2015","journal-title":"Trends Cell Biol"},{"key":"key20200714083746_b7-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1158\/0008-5472.CAN-12-0122","article-title":"Tumor microenvironment complexity: Emerging roles in cancer therapy","volume":"72","author":"Swartz","year":"2012","journal-title":"Cancer Res"},{"key":"key20200714083746_b8-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"key":"key20200714083746_b9-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00262-013-1434-6","article-title":"Immune-suppressive properties of the tumor microenvironment","volume":"62","author":"Becker","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"key20200714083746_b10-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"key20200714083746_b11-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"key20200714083746_b12-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1085\/jgp.8.6.519","article-title":"The metabolism of tumors in the body","volume":"8","author":"Warburg","year":"1927","journal-title":"J Gen Physiol"},{"key":"key20200714083746_b13-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"key20200714083746_b14-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.smim.2016.09.001","article-title":"Nutrient sensing, signal transduction and immune responses","volume":"28","author":"Walls","year":"2016","journal-title":"Semin Immunol"},{"key":"key20200714083746_b15-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/sj.cdd.4401073","article-title":"T cell apoptosis by tryptophan catabolism","volume":"9","author":"Fallarino","year":"2002","journal-title":"Cell Death Differ"},{"key":"key20200714083746_b16-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.it.2012.10.001","article-title":"Indoleamine 2,3 dioxygenase and metabolic control of immune responses","volume":"34","author":"Munn","year":"2013","journal-title":"Trends Immunol"},{"key":"key20200714083746_b17-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"e1792","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"key20200714083746_b18-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/nrc1877","article-title":"Fibroblasts in cancer","volume":"6","author":"Kalluri","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"key20200714083746_b19-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key20200714083746_b20-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1158\/2326-6066.CIR-14-0002","article-title":"The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance","volume":"2","author":"Fearon","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"key20200714083746_b21-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/1471-2407-11-245","article-title":"FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Cancer"},{"key":"key20200714083746_b22-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.semcdb.2009.10.002","article-title":"Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression","volume":"21","author":"Shimoda","year":"2010","journal-title":"Semin Cell Dev Biol"},{"key":"key20200714083746_b23-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3748\/wjg.v20.i9.2237","article-title":"Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies","volume":"20","author":"Rucki","year":"2014","journal-title":"World J Gastroenterol"},{"key":"key20200714083746_b24-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"key":"key20200714083746_b25-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nri3064","article-title":"The parallel lives of angiogenesis and immunosuppression: Cancer and other tales","volume":"11","author":"Motz","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"key20200714083746_b26-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.neo.2014.07.003","article-title":"Tumor interstitial fluid pressure-a link between tumor hypoxia, microvascular density, and lymph node metastasis","volume":"16","author":"Rofstad","year":"2014","journal-title":"Neoplasia"},{"key":"key20200714083746_b27-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"key":"key20200714083746_b28-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","article-title":"Molecular mechanisms and clinical applications of angiogenesis","volume":"473","author":"Carmeliet","year":"2011","journal-title":"Nature"},{"key":"key20200714083746_b29-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/359843a0","article-title":"Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis","volume":"359","author":"Shweiki","year":"1992","journal-title":"Nature"},{"key":"key20200714083746_b30-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"2746","DOI":"10.1158\/0008-5472.CAN-11-1272","article-title":"Modulation of microenvironment acidity reverses anergy in human and murine tumor-infiltrating T lymphocytes","volume":"72","author":"Calcinotto","year":"2012","journal-title":"Cancer Res"},{"key":"key20200714083746_b31-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/ijc.29519","article-title":"HIF-1 at the crossroads of hypoxia, inflammation, and cancer","volume":"138","author":"Balamurugan","year":"2016","journal-title":"Int J Cancer"},{"key":"key20200714083746_b32-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.molcel.2011.07.012","article-title":"Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition","volume":"43","author":"Wu","year":"2011","journal-title":"Mol Cell"},{"key":"key20200714083746_b33-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1586\/14737140.2015.1059279","article-title":"The importance of the tumor microenvironment in the therapeutic management of cancer","volume":"15","author":"Pottier","year":"2015","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20200714083746_b34-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20200714083746_b35-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/MOG.0000000000000196","article-title":"Pancreatic stellate cell: Physiologic role, role in fibrosis and cancer","volume":"31","author":"Apte","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"key":"key20200714083746_b36-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1158\/1078-0432.CCR-11-3114","article-title":"The pancreas cancer microenvironment","volume":"18","author":"Feig","year":"2012","journal-title":"Clin Cancer Res"},{"key":"key20200714083746_b37-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1172\/JCI24015","article-title":"NO mediates mural cell recruitment and vessel morphogenesis in murine melanomas and tissue-engineered blood vessels","volume":"115","author":"Kashiwagi","year":"2005","journal-title":"J Clin Invest"},{"key":"key20200714083746_b38-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/sj.bjc.6603796","article-title":"High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile","volume":"96","author":"Baldewijns","year":"2007","journal-title":"Br J Cancer"},{"key":"key20200714083746_b39-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/427695a","article-title":"Pathology: Cancer cells compress intratumour vessels","volume":"427","author":"Padera","year":"2004","journal-title":"Nature"},{"issue":"736\u2013749","key":"key20200714083746_b40-ol-0-0-9219","first-page":"e18","article-title":"An immune atlas of clear cell renal cell carcinoma","volume":"169","author":"Chevrier","year":"2017","journal-title":"Cell"},{"issue":"750\u2013765","key":"key20200714083746_b41-ol-0-0-9219","first-page":"e17","article-title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","volume":"169","author":"Lavin","year":"2017","journal-title":"Cell"},{"key":"key20200714083746_b42-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"131","DOI":"10.5483\/BMBRep.2013.46.3.036","article-title":"Impact of tumour associated macrophages in pancreatic cancer","volume":"46","author":"Mielgo","year":"2013","journal-title":"BMB Rep"},{"key":"key20200714083746_b43-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","article-title":"CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans","volume":"331","author":"Beatty","year":"2011","journal-title":"Science"},{"key":"key20200714083746_b44-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1158\/0008-5472.CAN-10-2907","article-title":"Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer","volume":"71","author":"Tosolini","year":"2011","journal-title":"Cancer Res"},{"key":"key20200714083746_b45-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"key20200714083746_b46-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"key20200714083746_b47-ol-0-0-9219","article-title":"A Mini-review for cancer immunotherapy: Molecular understanding of PD-1\/PD-L1 pathway & translational blockade of immune checkpoints","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci"},{"key":"key20200714083746_b48-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/532162a","article-title":"Cocktails for cancer with a measure of immunotherapy","volume":"532","author":"Ledford","year":"2016","journal-title":"Nature"},{"key":"key20200714083746_b49-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"key20200714083746_b50-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s40425-015-0072-2","article-title":"Tumor immunology and cancer immunotherapy: Summary of the 2014 SITC primer","volume":"3","author":"Page","year":"2015","journal-title":"J Immunother Cancer"},{"key":"key20200714083746_b51-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1517\/13543784.2015.991819","article-title":"Nivolumab for the treatment of cancer","volume":"24","author":"Gunturi","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"key20200714083746_b52-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"key20200714083746_b53-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on t-cell infiltration and pd-l1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"key":"key20200714083746_b54-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","article-title":"Combination cancer immunotherapies tailored to the tumour microenvironment","volume":"13","author":"Smyth","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200714083746_b55-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/2326-6066.CIR-17-0175","article-title":"Subversion of NK-cell and TNF\u03b1 immune surveillance drives tumor recurrence","volume":"5","author":"Kottke","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"key20200714083746_b56-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/01.COT.0000521698.43783.ba","article-title":"U.S. Food and drug administration: Treatment approved for Any Solid tumor with biomarker","volume":"39","year":"2017","journal-title":"Onco Times"},{"key":"key20200714083746_b57-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"key20200714083746_b58-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"key20200714083746_b59-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1120\u20131133","key":"key20200714083746_b60-ol-0-0-9219","first-page":"e17","article-title":"Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade","volume":"170","author":"Wei","year":"2017","journal-title":"Cell"},{"key":"key20200714083746_b61-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2016","journal-title":"Oncoimmunology"},{"key":"key20200714083746_b62-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"key20200714083746_b63-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"e0150084","DOI":"10.1371\/journal.pone.0150084","article-title":"Poxvirus-based active immunotherapy with PD-1 and LAG-3 dual immune checkpoint inhibition overcomes compensatory immune regulation, Yielding complete tumor regression in mice","volume":"11","author":"Foy","year":"2016","journal-title":"PLoS One"},{"key":"key20200714083746_b64-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1172\/JCI90499","article-title":"Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer","volume":"127","author":"Taylor","year":"2017","journal-title":"J Clin Invest"},{"key":"key20200714083746_b65-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"6165","DOI":"10.1158\/1078-0432.CCR-16-2677","article-title":"Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40","volume":"23","author":"Messenheimer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20200714083746_b66-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1158\/2326-6066.CIR-17-0292","article-title":"Concurrent PD-1 blockade negates the effects of OX40 agonist antibody in combination immunotherapy through inducing T-cell apoptosis","volume":"5","author":"Shrimali","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"key20200714083746_b67-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1021\/acsmedchemlett.6b00391","article-title":"INCB24360 (Epacadostat), a highly potent and selective indoleamine-2,3-dioxygenase 1 (IDO1) inhibitor for immuno-oncology","volume":"8","author":"Yue","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"key20200714083746_b68-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"5427","DOI":"10.1158\/1078-0432.CCR-15-0420","article-title":"Molecular pathways: Targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy","volume":"21","author":"Zhai","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20200714083746_b69-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1158\/1078-0432.CCR-16-2272","article-title":"First-in-human phase I study of the oral inhibitor of indoleamine 2,3-dioxygenase-1 epacadostat (INCB024360) in patients with advanced solid malignancies","volume":"23","author":"Beatty","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20200714083746_b70-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"22928","DOI":"10.18632\/oncotarget.8216","article-title":"A phase I study of indoximod in patients with advanced malignancies","volume":"7","author":"Soliman","year":"2016","journal-title":"Oncotarget"},{"key":"key20200714083746_b71-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"O7","DOI":"10.1186\/2051-1426-3-S2-O7","article-title":"Preliminary results from a Phase I\/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers","volume":"3","author":"Gangadhar","year":"2015","journal-title":"J Immunother Cancer"},{"key":"key20200714083746_b72-ol-0-0-9219","first-page":"1198","article-title":"Inhibition of HIF-1\u03b1 by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo","volume":"7","author":"Zhu","year":"2017","journal-title":"Am J Cancer Res"},{"key":"key20200714083746_b73-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s00280-013-2362-z","article-title":"Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1\u03b1), in patients with refractory solid tumors","volume":"73","author":"Jeong","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20200714083746_b74-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3892\/or.2014.3655","article-title":"Lactate promotes resistance to glucose starvation via upregulation of Bcl-2 mediated by mTOR activation","volume":"33","author":"Huang","year":"2015","journal-title":"Oncol Rep"},{"key":"key20200714083746_b75-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10637-013-9999-7","article-title":"A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer","volume":"32","author":"Schelman","year":"2014","journal-title":"Invest New Drugs"},{"key":"key20200714083746_b76-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s12885-015-1382-y","article-title":"Optimisation of immunofluorescence methods to determine MCT1 and MCT4 expression in circulating tumour cells","volume":"15","author":"Kershaw","year":"2015","journal-title":"BMC Cancer"},{"key":"key20200714083746_b77-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.biocel.2015.04.008","article-title":"The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy","volume":"64","author":"Tarallo","year":"2015","journal-title":"Int J Biochem Cell Bio"},{"key":"key20200714083746_b78-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/bjc.2017.69","article-title":"Personalising and targeting antiangiogenic resistance: A complex and multifactorial approach","volume":"116","author":"Bueno","year":"2017","journal-title":"Br J Cancer"},{"key":"key20200714083746_b79-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nature21724","article-title":"Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming","volume":"544","author":"Tian","year":"2017","journal-title":"Nature"},{"key":"key20200714083746_b80-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/annonc\/mdt228","article-title":"A multinational phase II trial of bevacizumab with low-dose interferon-\u03b12a as first-line treatment of metastatic renal cell carcinoma: BEVLiN","volume":"24","author":"Melichar","year":"2013","journal-title":"Ann Oncol"},{"key":"key20200714083746_b81-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","article-title":"Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial","volume":"32","author":"Rini","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20200714083746_b82-ol-0-0-9219","first-page":"1639","article-title":"A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20200714083746_b83-ol-0-0-9219","first-page":"44","article-title":"Stromal antigen targeting by a humanised monoclonal antibody: An early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer","volume":"26","author":"Hofheinz","year":"2003","journal-title":"Onkologie"},{"key":"key20200714083746_b84-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.it.2015.10.003","article-title":"Interleukin-2: Biology, design and application","volume":"36","author":"Arenas-Ramirez","year":"2015","journal-title":"Trends Immunol"},{"key":"key20200714083746_b85-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol Ther"},{"key":"key20200714083746_b86-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J Exp Med"},{"key":"key20200714083746_b87-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"key20200714083746_b88-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.CIR-16-0197","article-title":"Immunological mechanisms underneath the efficacy of cancer therapy","volume":"4","author":"Galluzzi","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"key20200714083746_b89-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.canlet.2015.05.012","article-title":"Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges","volume":"365","author":"Teng","year":"2015","journal-title":"Cancer Lett"},{"key":"key20200714083746_b90-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1172\/JCI69219","article-title":"Radiation and immunotherapy: A synergistic combination","volume":"123","author":"Kalbasi","year":"2013","journal-title":"J Clin Invest"},{"key":"key20200714083746_b91-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/ijms15010927","article-title":"The effect of radiation on the immune response to cancers","volume":"15","author":"Park","year":"2014","journal-title":"Int J Mol Sci"},{"key":"key20200714083746_b92-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2217\/imt.14.111","article-title":"Rationale for combining immunotherapy with chemotherapy","volume":"7","author":"Dalgleish","year":"2015","journal-title":"Immunotherapy"},{"key":"key20200714083746_b93-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1053\/j.seminoncol.2015.05.007","article-title":"Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy","volume":"42","author":"Wargo","year":"2015","journal-title":"Semin Oncol"},{"key":"key20200714083746_b94-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20200714083746_b95-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/COC.0b013e3182868ec8","article-title":"Immune-priming of the tumor microenvironment by radiotherapy: Rationale for combination with immunotherapy to improve anticancer efficacy","volume":"38","author":"Shahabi","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"key20200714083746_b96-ol-0-0-9219","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.it.2016.04.010","article-title":"Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer","volume":"37","author":"Hughes","year":"2016","journal-title":"Trends Immunol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T09:37:22Z","timestamp":1594719442000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2018.9219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":96,"URL":"https:\/\/doi.org\/10.3892\/ol.2018.9219","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]}}}